The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The study included 102 overweight type 2 diabetes mellitus patients with a body mass index (BMI) of more than 25 in an open label study. They were advised intensive life style modification which was reinforced at each follow-up visit. In addition they were prescribed extended release metformin (XR) in a gradually increasing tolerable dose, starting with 0.5g twice a day after meals. In addition, hypertension and dyslipidemia, when present, were treated with appropriate recommended drugs. Those who completed a satisfactory regular follow-up for at least 12 months or more were then analyzed for changes in their anthropometric measurements and glycemic control.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 70 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 Diabetes Mellitus
BMI more than 25
Type 1 diabetes
presence of concomitant endocrinal disorder
non-overweight type 2 diabetes
type 2 diabetes with secondary failure to sulfonylurea and taking insulin
presence of proliferative retinopathy or chronic renal failure
known cirrhosis of liver
presence of active tuberculosis
known HIV disease or any active infection
major mental illness
failure to comply with the exercise advice due to physical incapacity (e.g., severe osteoarthritis, hemiparesis or any other disabling neurological disease)
present pregnancy (or planning pregnancy)
using any kind of hormones including oral contraceptives, systemic corticosteroids, nicotinic acid
use of anti-obesity drug within the past 3 months
chronic gastroparesis or chronic severe gastrointestinal symptoms
a history of gastric or duodenal ulcers
abdominal surgery within 1 year will not be included in the study
patients with congestive heart failure or overt nephropathy will also not be included, due to unreliability of anthropometric measurements in such subjects and the relative risk of lactic acidosis